drugset / Trial / NCT00107900
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the occurrence of deep vein thrombosis in patients having total hip replacement surgery.
Timeline
- Start
- 2005-01
- Primary completion
- 2005-12
- Completion
- 2005-12
Outcome
Missed primary endpoint
registry analysis (superiority or other test); 15mg BID vs 30mg QD vs 30mg BID vs 60mg QD vs 60mg BID vs 120mg QD; p = 0.238; Fisher Exact NCT00107900 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Edoxaban | Small molecule | 15 mg | Oral |
| Subject | Edoxaban | Small molecule | 30 mg | Oral |
| Subject | Edoxaban | Small molecule | 60 mg | Oral |
| Subject | Edoxaban | Small molecule | 120 mg | Oral |